Consumer News Experimental Drug Helped Alzheimer S Patients In Small Trial

The next big breakthroughs in Alzheimer’s science and treatment

The outlook for dementia care is changing fast. UC experts explain what that means for patients and families, and what it will take to keep the momentum growing. Read More

Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer’s, despite trial setback

Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two disappointing trials last month. Read More

Alzheimer’s pill could reduce brain decline in some high-risk patients, trial suggests

An experimental pill could slow memory loss and brain shrinkage in some Alzheimer’s patients, new research suggests. The pill, called ALZ-801 (valiltramiprosate), was shown to be effective in people ... Read More

Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment

By Deena Beasley and Julie Steenhuysen SAN DIEGO, Dec 3 (Reuters) - Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early ... Read More

Failed Semaglutide for Early Alzheimer’s Not the End of the Road?

A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet experts say the results provide important direction for future drug development ... Read More

J&J’s novel Alzheimer’s drug fails in key trial, dimming hopes for a hot target

A promising Alzheimer’s treatment failed to slow the progress of the disease, news that could dampen enthusiasm for a new class of potential medicines. Read More

GLP-1s Just Failed an Alzheimer’s Trial—Does That Mean the Brain Hype Is Over?

A large new trial falls short of experts’ expectations for combating the neurodegenerative disease. But there could still be hope on the horizon. Read More